Host: |
Rabbit |
Applications: |
WB |
Reactivity: |
Human/Mouse |
Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description: |
Rabbit polyclonal antibody anti-CXCL13 (21-109) is suitable for use in Western Blot research applications. |
Clonality: |
Polyclonal |
Conjugation: |
Unconjugated |
Isotype: |
IgG |
Formulation: |
PBS with 0.01% Thimerosal, 50% Glycerol, pH7.3. |
Purification: |
Affinity purification |
Dilution Range: |
WB 1:500-1:2000 |
Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
Gene Symbol: |
CXCL13 |
Gene ID: |
10563 |
Uniprot ID: |
CXL13_HUMAN |
Immunogen Region: |
21-109 |
Immunogen: |
Recombinant fusion protein containing a sequence corresponding to amino acids 21-109 of human CXCL13 (NP_006410.1). |
Immunogen Sequence: |
QGVLEVYYTSLRCRCVQESS VFIPRRFIDRIQILPRGNGC PRKEIIVWKKNKSIVCVDPQ AEWIQRMMEVLRKRSSSTLP VPVFKRKIP |
Tissue Specificity | Highest levels in liver, followed by spleen, lymph node, appendix and stomach. Low levels in salivary gland, mammary gland and fetal spleen. |
Function | Chemotactic for B-lymphocytes but not for T-lymphocytes, monocytes and neutrophils. Does not induce calcium release in B-lymphocytes. Binds to BLR1/CXCR5. |
Protein Name | C-X-C Motif Chemokine 13AngieB Cell-Attracting Chemokine 1Bca-1B Lymphocyte ChemoattractantCxc Chemokine BlcSmall-Inducible Cytokine B13 |
Database Links | Reactome: R-HSA-380108Reactome: R-HSA-418594 |
Cellular Localisation | Secreted |
Alternative Antibody Names | Anti-C-X-C Motif Chemokine 13 antibodyAnti-Angie antibodyAnti-B Cell-Attracting Chemokine 1 antibodyAnti-Bca-1 antibodyAnti-B Lymphocyte Chemoattractant antibodyAnti-Cxc Chemokine Blc antibodyAnti-Small-Inducible Cytokine B13 antibodyAnti-CXCL13 antibodyAnti-BCA1 antibodyAnti-BLC antibodyAnti-SCYB13 antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance